Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,701–9,800 of 15,747
Acute Hepatitis of Unknown Origin (AHUO)—The Puzzle Ahead
Sergi, C. M. (2022) · Diagnostics · doi:10.3390/diagnostics12051215 · Cited by 4
Miller, N. D., Gepstein, N. G., Cohen, D., Herzberger, E. H., Ram, H. S., Friedler, J. M., Sharon‐Weiner, M., Rahav, R., Indenbaum, V., Lustig, Y., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01345-9 · Cited by 4
“At the end of 2020, the FDA issued its first emergency use authorization for the Pfizer mRNA BioNtech COVID-19 vaccine [6, 7], with a reported 94%–95% efficacy in preventing COVID-19 [8].”
(2022) · doi:10.1101/2022.03.23.22272804 · Cited by 4
“For each comparison period we estimated hazard ratios (HRs) comparing: (1) BNT162b2 vs unvaccinated; (2) ChAdOx1 vs unvaccinated; (3) BNT162b2 vs ChAdOx1.”
MethodChung, C. W., Irudayaraj, P., Lallow, E. O., Xu, Z., Park, Y. K., Kudchodkar, S. B., Montaner, L. J., Srinivasan, A., & Muthumani, K. (2024) · Frontiers in Virology · doi:10.3389/fviro.2024.1399993 · Cited by 7
Tuaillon, É., Pisoni, A., Veyrenche, N., Rafasse, S., Niel, C., Gros, N., Muriaux, D., Picot, M., Aouinti, S., van de Perre, P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18041-x · Cited by 6
Park, J. Y., Kim, J., Park, S., Hwang, Y. I., Kim, H. I., Jang, S. H., Jung, K., Kim, Y. K., Kim, H. A., & Lee, I. J. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.072 · Cited by 4
Akech, G. M., Kanyike, A. M., Nassozi, A. G., Aguti, B., Nakawuki, A., Kimbugwe, D., Kiggundu, J., Maiteki, R., Mukyala, D., Bongomin, F., et al. (2022) · medRxiv · doi:10.1101/2022.07.11.22277490 · Cited by 3
Huygens, S., Preijers, T., Swaneveld, F. H., Budde, I. K., GeurtsvanKessel, C. H., Koch, B. C. P., & Rijnders, B. J. A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01351-w · Cited by 5
RNA vaccines for cancer: revolutionizing immunization strategies
Huang, D., Zhang, J., Zeng, X., Zhang, Y., & Song, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.09.003 · Cited by 5
Cámara, J., González-Díaz, A., Barrabeig, I., Fernández-Huerta, M., Calatayud, L., Niubó, J., Martí, S., Domínguez, M. Á., & Ardanuy, C. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.026 · Cited by 4
“COVID-19 vaccines have been shown to be effective in preventing disease caused by SARS-CoV-2 [1] which has led to a reduction in the incidence rate of severe disease in countries with high vaccination rates [2].”
BackgroundImpfung zur Vorbeugung der COVID-19-Erkrankung sowie Impfpriorisierung bei Epilepsie
Strzelczyk, A., Knake, S., Holtkamp, M., Schulze‐Bonhage, A., Lemke, J. R., von Spiczak, S., Berkenfeld, R., Rosenow, F., Brandt, C., & Schmitt, F. C. (2021) · Clinical Epileptology · doi:10.1007/s10309-021-00404-5 · Cited by 4
Ebrahim, S., Blose, N., Gloeck, N. R., Hohlfeld, A., Balakrishna, Y., Muloiwa, R., Gray, A., Parrish, A., Cohen, K., Lancaster, R., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002676 · Cited by 5
Chatterjee, D., Kurup, D., & Smeyne, R. J. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00925-0 · Cited by 5
Pelzek, A. J., Ebtehaj, S., Lulo, J. E., Zhang, L., Balduf, O., Dolan, L., Zhang, C., Wan, S., An, G., Kankam, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.06.479332 · Cited by 4
An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics
Natsume‐Kitatani, Y., Kobiyama, K., Igarashi, Y., Aoshi, T., Nakatsu, N., Tripathi, L. P., Ito, J., Nyström-Persson, J., Kosugi, Y., Osorio, R. S. A., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.07.005 · Cited by 7
MacFadden, D. R., Brown, K. A., Buchan, S. A., Chung, H., Kozak, R., Kwong, J. C., Manuel, D. G., Mubareka, S., & Daneman, N. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac156 · Cited by 4
Fontenot, H. B., Mattheus, D. J., Lim, E., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1947097 · Cited by 4
Sáez‐Peñataro, J., Calvo, G., Bascuas, J., Mosquera, M. C., Marcos, M. Á., Egri, N., & Torres, F. (2024) · Vaccines · doi:10.3390/vaccines12060665 · Cited by 5
“In these studies, the most frequently reported adverse reactions (ARs) were local (e.g., pain at the injection site) or systemic ARs (e.g., fever, myalgia, or malaise) [1,2].”
BackgroundUnderstanding of COVID-19 from infection–fatality ratio
Gu, X., & Cao, B. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00281-1 · Cited by 6
Case report: Case series of isolated acute pericarditis after SARS-CoV-2 vaccinations
Ochs, M. M., Haass, M., Hagstotz, S., Giuşcă, S., & Korosoglou, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.990108 · Cited by 5
Özen, S., Gül, A. E. K., Gülhan, B., Özbülbül, N. I., Yüksek, S. K., Terin, H., Mustafaoğlu, Ö., Bayraktar, P., Ece, İ., Çetin, İ. İ., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2157478 · Cited by 5
Management of SARS-CoV-2 and Persistent Viral Detection in Solid Organ Transplant Recipients
de Castro, K. L. P., Naik, C. A., Spak, C. W., Askar, M. Z., Pittmon, L., Williams, J. D., Vandervest, K., Endicott-Yazdani, T. R., Grazia, T. J., Gottlieb, R., et al. (2024) · Current Pulmonology Reports · doi:10.1007/s13665-024-00338-z · Cited by 4
“Both vaccine trials reached primary safety endpoints, and common side effects were managed with over-the-counter analgesia and antipyretics [68, 69].”
Deep learning models for predicting RNA degradation via dual crowdsourcingPreprint
Wayment-Steele, H. K., Kladwang, W., Watkins, A. M., Kim, D. S., Tunguz, B., Reade, W., Demkin, M., Romano, J., Wellington-Oguri, R., Nicol, J. J., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2110.07531 · Cited by 6
AlRuthia, Y., Al-Salloum, H. F., Almohammed, O., Alqahtani, A., Al-Abdulkarim, H. A., Alsofayan, Y. M., Almudarra, S., Alqahtani, S., Almutlaq, A., Alabdulkareem, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10020323 · Cited by 3
“These COVID-19 vaccines, such as Pfizer–BioNTech (BNT162b2) [21], Moderna (mRNA-1273) [22], Oxford–AstraZeneca (ChAdOx1 nCoV-19) [23], Johnson & Johnson (Ad26.”
Morimoto, H., Hayano, S., Ozawa, N., Ogura, Y., Usui, H., Usami, T., Ohse, A., Otsuka, M., Miyachi, M., & TOKURA, Y. (2021) · Vaccines · doi:10.3390/vaccines9121421 · Cited by 4
“Recently, several vaccines against SARS-CoV-2 have begun to be used worldwide, and it is evident that they can reduce the infection rate, disease severity, and transmission rate and contribute to disease control [2,3].”
BackgroundResultInfluentialKang, H. J., Lee, H. J., Baek, J. Y., Kim, H., Lee, Y. J., Choi, J., Jeong, H.-S., Kim, E. H., Peck, K. R., & Ko, J. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102794 · Cited by 5
Junger, N., & Hirsch, O. (2024) · Cureus · doi:10.7759/cureus.57960 · Cited by 13
“The authors based their decision aid just on the regulatory study that was published in the New England Journal of Medicine [165] and which was criticized for several methodological problems [16,23,166].”
BackgroundHinz, A., Stankiewicz, S., Litewka, J. J., Ferdek, P. E., Sochalska, M., & Bzowska, M. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479710 · Cited by 4
“18–20 Most studies have focused exclusively on elucidating the immediate effects following the intravenous administration of PEGylated drugs, including testing for complement activation or anti-PEG antibodies.”
Mukhopadhyay, L., Gupta, N., Yadav, P. D., & Aggarwal, N. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_2544_21 · Cited by 6
Cai, X., Teo, N. K. S., Fan, B., Thang, S. H., Drummond, C. J., Tran, N. L., & Zhai, J. (2025) · Polymer Chemistry · doi:10.1039/d4py01300j · Cited by 3
Bergami, F., Arena, F., Pattonieri, E. F., Gregorini, M., Meloni, F., Abelli, M., Ticozzelli, E., Testa, G., Lilleri, D., Cassaniti, I., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12061509 · Cited by 4
McCormack, M. J., Scott, S., Logan, N., Raveendran, S., Newman, J., Santos, I. A., Bailey, D., Murcia, P. R., Thomson, E. C., Hosie, M. J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105760 · Cited by 3
Xue, H., Kemp, T. J., North, H. F., Roche, N., Hickey, T. E., & Pinto, L. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1629473 · Cited by 6
Malkawi, W. I., Laird, N. Z., Phruttiwanichakun, P., et al. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.008 · Cited by 4
Rose, A., Nicolay, N., Martín, V. S., Mazagatos, C., Petrović, G., Niessen, F., Machado, A., Launay, O., Denayer, S., Seyler, L., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.47.2300186 · Cited by 5
Tang, C., Yuan, L., Xie, Y., Yang, Y., Zhou, Y., Wang, J., Yang, H., Peng, R., Xu, J., Yu, W., et al. (2026) · MedComm · doi:10.1002/mco2.70614 · Cited by 4
“Characterized by high immunogenicity and rapid development capabilities, mRNA vaccines have made significant contributions to pandemic containment during the COVID-19 outbreak [ 9 ].”
Roche, R., Odeh, N., Andar, A. U., Tulapurkar, M. E., & Roche, J. A. (2023) · Microorganisms · doi:10.3390/microorganisms11081963 · Cited by 4
Ugrani, S. (2023) · European Biophysics Journal · doi:10.1007/s00249-023-01695-4 · Cited by 3
“The magnitude of its impact on human health and virtually all life aspects urged the scientific and medical communities to develop treatments, resulting in the discovery of vaccines for the original SARS-Cov-2 in record time (Polack et al. 2020; Tanne 2020).”
Hammad, N., Kadry, H. M., Malek, M. M., Bahgat, S. M., Abdelsalam, N. M., Afifi, A. H. M., & Abo-Alella, D. (2022) · Vaccines · doi:10.3390/vaccines10101706 · Cited by 5
“mRNA vaccines, such as BNT162b2 and mRNA-1273, demo strated an efficacy of 95% n are currently used in several countries [17,18].”
BackgroundMethodMohr, N. M., Plumb, I. D., Harland, K. K., et al. (2022) · medRxiv · doi:10.1101/2022.02.16.22271092 · Cited by 4
N‐terminal modification of an LAH4‐derived peptide increases mRNA delivery in the presence of serum
Dussouillez, C., Lointier, M., Sebane, M., Fournel, S., Bechinger, B., & Kichler, A. (2024) · Journal of Peptide Science · doi:10.1002/psc.3597 · Cited by 4
“The recently developed coronavirus SARS-CoV-2 vaccines highlighted the great therapeutic potential of mRNA in vaccination [1].”
MethodEosinophilic lymph node abscesses following a COVID-19 vaccination: A case report
Kaya, A., Kaya, S. Y., Abul, A., et al. (2023) · Journal of the National Medical Association · doi:10.1016/j.jnma.2023.01.003 · Cited by 4
Seekircher, L., Bánki, Z., Kimpel, J., Rössler, A., Schäfer, H., Falkensammer, B., Bante, D., Forer, L., Schönherr, S., Harthaller, T., et al. (2022) · medRxiv · doi:10.1101/2022.04.19.22273872 · Cited by 3
“36 All recorded SARS-CoV-2 infections, including dates of infections, symptoms, and clinical course, underwent rigorous validation in structured telephone interviews.”
Polymerized porin as a novel delivery platform for coronavirus vaccine
Yang, Z., Hua, L., Yang, M., Li, W., Ren, Z., Zheng, X. W., Chen, H., Long, Q., Bai, H., Huang, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01469-8 · Cited by 4
“Inactivated vaccines [2], viral vector vaccines [3], subunit vaccines [4], mRNA vaccines [5], and DNA vaccines against SARS-CoV-2 have proven the effectiveness of different SARS-CoV-2 vaccines [6].”
BackgroundKim, W. (2024) · Immune Network · doi:10.4110/in.2024.24.e28 · Cited by 7
Fabricius, D., Ludwig, C., Proffen, M., Hägele, J., Scholz, J. A. M., Vieweg, C., Rode, I., Hoffmann, S., Körper, S., Schrezenmeier, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580448 · Cited by 4
A Rapid Saliva Test for Monitoring Immune Protection against SARS -CoV-2 and its VariantsPreprint
Momyer, V. S. A., Dixon, S., Liu, Q. J., Wee, B., Chen, T., Petropoulos, A. E., & Sang, L. J. (2021) · medRxiv · doi:10.1101/2021.07.09.21260224 · Cited by 4
“Immunity to SARS-CoV-2 gained either through infection or vaccination has been shown to confer protection against reinfection and/or reduce the risk of clinically severe outcomes (1-3).”
BackgroundArino, H., Muramae, N., Okano, M., Mori, K., Otsui, K., & Sakaguchi, K. (2022) · Cureus · doi:10.7759/cureus.24952 · Cited by 7
“Their efficacy in preventing severe respiratory conditions has been established [3-5].”
BackgroundCarabajal-Johnson, A., Qato, D. M., Fleming, S. P., Faulkner, R., & Wastila, L. J. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.10.025 · Cited by 4
COVID-19 Vaccines and Myocardial Injury
Bluemke, D. A. (2023) · Radiology · doi:10.1148/radiol.232244 · Cited by 4
Murtada, R., Carbonnel, M., Revaux, A., Favre-Inhofer, A., & Ayoubi, J.-M. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.564145 · Cited by 4
“Efficacy and safety of RNA vaccine and OxfordAstra Zeneca for people under 65 years has been proven (21, 22).”
BackgroundCopolymers of NVAm and NVP for Efficient Gene Delivery
Fielitz, T., Raab, C., Tkachenko, V. V., Oleszkiewicz, K. M., Fuchs, H., & Hartlieb, M. (2026) · ACS Polymers Au · doi:10.1021/acspolymersau.5c00167 · Cited by 4
COVID-19 infection among healthcare workers in an oncology hospital
İskender, G., Mert, D., Avşar, Z., Kölgelier, S., & Ertek, M. (2023) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.17404 · Cited by 4
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccinationPreprint
Nicolson, P. L. R., Montague, S. J., Smith, C. W., et al. (2021) · medRxiv · doi:10.1101/2021.08.17.21262138 · Cited by 4
“(AZD1222) which has been developed by Oxford-AstraZeneca (2,3).”
BackgroundZaufishan, Z., Usman, M. H., Mumtaz, K. F., Bilal, R., Arshad, A., & Khan, H. M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1084017 · Cited by 4
“Comparable vaccine effectiveness of 90–100% was observed in population subgroups defined by age, ethnicity, gender, baseline BMI, and comorbidities (11).”
BackgroundFilling the Gap Until Full Vaccine Deployment in the War on Coronavirus Disease-19
Mattoli, S. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00394-3 · Cited by 4
Hunter, E., Koutsothanasi, C., Wilson, A. J., Santos, F. C., Salter, M., Westra, J. W., Powell, R., Dring, A. M., Brajer, P., Egan, B., et al. (2021) · medRxiv · doi:10.1101/2021.06.21.21259145 · Cited by 4
Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves
Rahman, A., Roy, K. J., Deb, G. K., Ha, T., Rahman, S., Aktar, M. K., Ali, M. I., Kafi, M. A., & Choi, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713130 · Cited by 5
“3% protection against the Alpha variant [11].”
Valletta, M., Canevelli, M., D’Antonio, F., Trebbastoni, A., Talarico, G., Campanelli, A., Monti, M. S., Vita, A. D., Salati, E., Imbriano, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220077 · Cited by 5
Tut, G., Lancaster, T., Krutikov, M., Sylla, P., Bone, D., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3990239 · Cited by 3
多賀谷, 悦., Kikuchi, K., Mitsuda, T., Ebihara, F., Maruyama, T., Hamada, Y., Kimura, T., Unagami, K., Kanzawa, T., Sekiguchi, H., et al. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101777 · Cited by 12
An immunologist's perspective on anti-COVID-19 vaccines
Milota, T., Strizova, Z. O., Smetanová, J., & Šedivá, A. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000788 · Cited by 6
COVID-19 Vaccine Global Information Management Through Bibliometrics
Tchuente, D., Nyawa, S., & Wamba, S. F. (2021) · Journal of Global Information Management · doi:10.4018/jgim.294578 · Cited by 4
Tuli, H. S., Sak, K., Aggarwal, P., Iqubal, A., Upadhaya, S. K., Kaur, J., Kaur, G., & Aggarwal, D. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.763687 · Cited by 4
Evaluation of the United States COVID-19 Vaccine Allocation StrategyPreprint
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C. (2021) · medRxiv · doi:10.1101/2021.07.01.21259870 · Cited by 4
Boulon, R., Mazeaud, C., Farahani, M. D., Broquière, M., Iddir, M., Charpentier, T., Anton, A., Ayotte, Y., Woo, S., Lamarre, A., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00512 · Cited by 6
Human T Cell Responses to Flavivirus Vaccines
Wullimann, D., & Ljunggren, H. (2025) · European Journal of Immunology · doi:10.1002/eji.70027 · Cited by 8
Soldà, G., Barvas, E., Lenzi, J., Valerio, Z. D., Fauci, G. L., Guttmann, S., Riccardi, R., Fantini, M. P., Salussolia, A., Montalti, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10030370 · Cited by 4
“Gam-COVID-Vac vaccine consists of two doses, respectively 0.5 mL of rAd26 and 0.5 mL of rAd5 [15], while Pfizer-BioNTech (Pfizer, New York City, NY, USA) has two 30-µg doses of BNT162b2 [16].”
BackgroundInfluentialApplication in gene therapy and DNA/RNA vaccines
Limeres, M. J., Toscanini, M. A., Devoto, T. B., Ladetto, M. F., Castro, G. R., & Cuestas, M. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91229-7.00001-5 · Cited by 5
ATAGI Targeted Review 2021: the national COVID-19 vaccination program
Jayasinghe, S. H., Patel, C., Armstrong, L., Chiu, C., Macartney, K. K., Flanagan, K. L., Gibney, K. B., Giles, M., Crawford, N. W., Cheng, A., et al. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.20 · Cited by 3
Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles
Elfayres, G., Paswan, R. R., Sika, L., Girard, M.-P., Khalfi, S., Letanneur, C., Milette, K., Singh, A., Kobinger, G., & Berthoux, L. (2023) · Journal of Virological Methods · doi:10.1016/j.jviromet.2023.114835 · Cited by 4
Olsen, R., Christensen, P., Long, S., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Ojeda-Saavedra, M., et al. (2021) · medRxiv · doi:10.1101/2021.05.20.21257552 · Cited by 3
Muraoka, D., Moi, M. L., Muto, O., Nakatsukasa, T., Deng, S., Takashima, C., Yamaguchi, R., Sawada, S., Hayakawa, H., Nguyen, T. T. N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00961-6 · Cited by 4
Ongun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4
Vaccines for preventing infections in adults with haematological malignancies
Zorger, A.-M., Hirsch, C., Baumann, M., Feldmann, M., Bröckelmann, P. J., Mellinghoff, S. C., Monsef, I., Skoetz, N., & Kreuzberger, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015530.pub2 · Cited by 8
Hematopoietic stem cell therapy with gene modification to treat sickle cell disease
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf042 · Cited by 8
Ravera, F., Dameri, M., Lombardo, I., Stabile, M., Becherini, P., Fallani, N., Scarsi, C., Cigolini, B., Gentilcore, G., Domnich, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115838 · Cited by 5
Resilience to emerging infectious diseases and the importance of scientific innovation
Wilson, C., & Thomson, E. C. (2024) · Future Healthcare Journal · doi:10.1016/j.fhj.2024.100023 · Cited by 4
Engineered migrasomes provide a robust and thermally stable vaccination platform
Wang, D., Wang, H., Wan, W., Zhu, Z., Sho, T., Zheng, Y., Zhang, X., Dou, L., Ding, Q., Yu, L., et al. (2025) · eLife · doi:10.7554/elife.97621.3 · Cited by 10
Yaseen, A. R., Suleman, M., Afzal, M., Usama, H., Ashfaq, W., Firyal, S., Arif, A., Latif, A., Ali, A., & Qadri, A. S. (2025) · The Nucleus · doi:10.1007/s13237-025-00587-6 · Cited by 4
The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
Nicolai, E., Tomassetti, F., Pelagalli, M., Sarubbi, S., Minieri, M., Nisini, A., Nuccetelli, M., Ciotti, M., Pieri, M., & Bernardini, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102661 · Cited by 5
Nam, S. Y., Jeon, S. W., Jung, D. K., & Heo, S. J. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0089 · Cited by 5
The type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8 + T cell responsesPreprint
Phan, A. T., Aunins, E., Cruz-Morales, E., Dwivedi, G., Bunkofske, M. E., Eberhard, J. N., Aldridge, D. L., Said, H., Banda, O., Tam, Y. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.16.633383 · Cited by 10
Coronavirus disease 2019 vaccines: landscape of global studies and potential risks
Jiang, H.-D., Tao, Y., Jia, S., Li, J., & Zhu, F. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001688 · Cited by 6
“0% effective for preventing COVID-19 in people aged >16 years old.([10]) Similar to BNT162b2, the mRNA-1273 vaccine was also found in a phase 3 clinical trial, conducted in approximately 30,000 people in 99 regions of the United States, to cause pain at the injection site as the most common adverse reaction to vaccina…”
BackgroundTransport and optimal control of vaccination dynamics for COVID-19
Zaitri, M. A., Bibi, M. O., & Torres, D. F. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-32-390504-6.00007-3 · Cited by 4
“A first interim efficacy analysis was conducted by an external, independent Data Monitoring Committee from the Phase 3 clinical study, and the case split, between vaccinated individuals and those who received the placebo, indicates a vaccine efficacy rate above 90%, at seven days after the second dose, of the 94 cases…”
MethodSelf-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants
Herfst, S., & de Vries, R. D. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00734-x · Cited by 6
COVID-19 vaccine hesitancy prevalence in Mexico: A systematic review and metanalysis
Ramonfaur, D., Limaye, R. J., Hinojosa-Gonzalez, D. E., Barrera, F. J., Rodriguez-Gomez, G. P., & Castillo‐Salgado, C. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100488 · Cited by 6
“[5] While several studies have examined the safety and effectiveness of COVID-19 vaccines,[6 – 9] a considerable proportion of individuals worldwide remain unwilling to be immunized .”
BackgroundMonschein, T., Zrzavy, T., Löbermann, M., Winkelmann, A., Berger, T., Rommer, P. S., Hartung, H., & Zettl, U. K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01154-5 · Cited by 3
“Beim BionTech/ Pfizer-Impfstoff wurden vier schwere Nebenwirkungen (SAEs) berichtet (Schulterverletzung im Zusammenhang mit der Impfstoffverabreichung, axilläre Lymphadenopathie rechts, paroxysmale ventrikuläre Arrhythmie und Parästhesie im rechten Bein; [56]).”
BackgroundSegundo, D. S., Comins-Boo, A., Lamadrid-Perojo, P., Irure-Ventura, J., Castillo-Otí, J. M., Wallman, R., Calvo-Montes, J., Méndez-Legaza, J. M., Baamonde-Calzada, C., Sánchez-Molina, I., et al. (2021) · Vaccines · doi:10.3390/vaccines9121429 · Cited by 2
“The vaccination against SARS-CoV-2 with BNT162b2 is safe and effective, conferring a 95% protection against COVID-19 in subjects over 16 years old [5], and reducing hospitalization and mortality.”
BackgroundTakagi, E., Terakura, S., Fujigaki, H., Okamoto, A., Miyao, K., Sawa, M., Morishita, T., Goto, T., Ozawa, Y., Nishida, T., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03648-1 · Cited by 4
Garrido, J. M., Martínez‐Rodríguez, D., Rodríguez‐Serrano, F., Sferle, S. M., & Villanueva, R. J. (2021) · Mathematics · doi:10.3390/math9101132 · Cited by 4
Saciuk, Y., Kertes, J., Mandel, M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3868853 · Cited by 4
Tawinprai, K., Jungsomsri, P., Pinijnai, O., Tavonvunchai, F., Lievjaroen, A., Suwannaroj, P., Siripongboonsitti, T., Porntharukchareon, T., Sornsamdang, G., & Ungtrakul, T. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2206360 · Cited by 4
Urological complications after COVID 19 vaccine according to age, sex and manufacturer
Shim, S. R., Kim, K. T., Park, E., Pyun, J. H., Kim, J. H., & Chung, B. I. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04481-1 · Cited by 3
“Although many of these events are carefully recorded and monitored, data regarding organ specific complications related to vaccine administration are scarce [1, 8].”
Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
Pandey, K., Jha, S., Chaliha, L. B., Gosai, H. B., & Patel, R. (2026) · Frontiers in Nanotechnology · doi:10.3389/fnano.2026.1860221 · Cited by 7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.